Delpharm has increased its capacity by acquiring and installing a new, fully Annex 1 compliant, sterile filling line, significantly increasing its production capacity for sterile vials or ...

AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).

Session ID: 2025-07-01:c3d96494478f7322ba15e67b Player Element ID: Vd5cd1b33_dfb7_4cb6_a47a_a289603d2ac9_6374240200112 ...

While advancements have been made in other oncogenic drivers like EGFR, ALK, and ROS1, the landscape for HER2 mutations has remained comparatively limited. Current treatment paradigms often rely on ...

Interim results from the DESTINY-Breast-09 trial, presented at ASCO Annual Meeting, suggest trastuzumab deruxtecan (T-DXd; Enhertu; AstraZeneca, Daiichi Sankyo) plus pertuzumab (Perjeta, Genentech ...

Food and Drug Administration Commissioner Martin Makary has proposed a dramatic expansion of the agency’s powers to speed up drug reviews, announcing on Tuesday a plan to evaluate new medicines that ...

Dive Brief: Actio Biosciences, a San Diego-based biotechnology startup, announced Wednesday it raised a $66 million Series B financing to support drug research it’s initially aiming at rare genetic ...

Enhertu is approved in the U.S. to treat certain breast, lung and gastric cancers, with 2024 sales from both companies topping $3.7 billion.